Lumosa Therapeutics Co., Ltd. (6535.TWO)
TWD 191.0
(-1.29%)
TWD 191.0
(-1.29%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -328.21 Million | -300.45 Million | -452.6 Million | -129.11 Million | -379.52 Million |
| Net Income | -250.08 Million | -504.44 Million | 95.94 Million | -322.56 Million | -240.93 Million |
| Depreciation & Amortization | 23.36 Million | 22.16 Million | 32.1 Million | 35.62 Million | 39.33 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 8.59 Million | 5.02 Million | 3.22 Million | - | - |
| Change in working capital | 6.17 Million | -41.2 Million | -58.88 Million | 195.22 Million | -145.24 Million |
| Other non-cash items | -10.43 Million | -5.21 Million | -3.19 Million | -3.31 Million | 326.37 Million |
| Investing Cash Flow | 240.58 Million | -69.2 Million | -36.98 Million | 6.36 Million | -15.52 Million |
| Investments in PPE | -15.01 Million | -2.28 Million | -576 Thousand | -680 Thousand | - |
| Acquisitions | - | 50 Million | - | - | 47.24 Million |
| Investment purchases | -945.87 Million | -1.12 Billion | -1.76 Billion | -756.35 Million | -967.15 Million |
| Sales/Maturities of investments | 1.19 Billion | 1.05 Billion | 1.72 Billion | 763.4 Million | 841.7 Million |
| Other Investing Activities | 7.3 Million | - | - | - | 1.43 Million |
| Financing Cash Flow | -3.94 Million | 46.16 Million | 431.27 Million | 852.57 Million | 7.33 Million |
| Debt repayment | -4.33 Million | - | - | - | -6.25 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 287 Thousand | 813 Thousand | 436.74 Million | 859.37 Million | 13.58 Million |
| Other Financing Activities | 98 Thousand | 50 Million | - | - | - |
| Accounts receivables | 2.15 Million | -5.73 Million | 7.99 Million | 277.46 Million | -264.3 Million |
| Accounts payables | 501 Thousand | -13.5 Million | 14.47 Million | -7.81 Million | 7.84 Million |
| Inventory | 4.76 Million | -26.29 Million | -50.61 Million | -7.77 Million | -23.91 Million |
| Other working capital | -1.24 Million | 4.33 Million | -30.74 Million | -66.65 Million | 135.13 Million |
| Cash at beginning of period | 516.84 Million | 840.31 Million | 898.63 Million | 168.8 Million | 556.32 Million |
| Cash at end of period | 425.24 Million | 516.84 Million | 840.31 Million | 898.63 Million | 168.8 Million |
| Capital Expenditure | -15.01 Million | -2.28 Million | -576 Thousand | -680 Thousand | - |
| Effect of forex changes on cash | -26 Thousand | 22 Thousand | -12 Thousand | 2000.00 | - |
| Net cash flow / Change in cash | -91.6 Million | -323.47 Million | -58.31 Million | 729.83 Million | -387.51 Million |
| Free Cash Flow | -343.22 Million | -302.74 Million | -453.17 Million | -129.79 Million | -379.52 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 67.32 Million | -117.59 Million | -250.08 Million | -119.52 Million | -122.01 Million | -152.5 Million |
| Depreciation & Amortization | 2.11 Million | 2.09 Million | 23.36 Million | 6.2 Million | 6.08 Million | 5.55 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 7.8 Million | 8.11 Million | 8.59 Million | 5.15 Million | 1.13 Million | 1.04 Million |
| Change in working capital | -4.55 Million | -16.18 Million | 6.17 Million | 24.27 Million | 9.98 Million | -14.49 Million |
| Other non-cash items | -114.74 Million | -1.51 Million | -10.43 Million | -3.2 Million | -2.04 Million | -3.28 Million |
| Investing Cash Flow | 100.95 Million | -93.87 Million | 240.58 Million | 145.08 Million | 89.62 Million | 5.87 Million |
| Investments in PPE | -450 Thousand | - | -15.01 Million | -2.51 Million | -10.37 Million | -700 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -111 Million | -341.37 Million | -945.87 Million | -102.57 Million | -346.5 Million | -161.1 Million |
| Sales/Maturities of investments | 212.4 Million | 247.5 Million | 1.19 Billion | 250.17 Million | 446.5 Million | 161.1 Million |
| Other Investing Activities | 105.4 Million | - | - | - | - | - |
| Financing Cash Flow | -1.02 Million | -1.04 Million | -3.94 Million | -993 Thousand | -1.08 Million | -1.08 Million |
| Debt repayment | -1.02 Million | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 287 Thousand | - | - | - |
| Other Financing Activities | -1.02 Million | - | 98 Thousand | 98 Thousand | - | - |
| Accounts receivables | -4.44 Million | 7.68 Million | 2.15 Million | 1.17 Million | 6.04 Million | -12.24 Million |
| Accounts payables | 240 Thousand | -1.46 Million | 501 Thousand | 1.46 Million | - | - |
| Inventory | -2.32 Million | 2.85 Million | 4.76 Million | -1.08 Million | 1.03 Million | 1.41 Million |
| Other working capital | 1.98 Million | -25.26 Million | -1.24 Million | 22.72 Million | 2.9 Million | -3.66 Million |
| Cash at beginning of period | 250.67 Million | 425.24 Million | 516.84 Million | 355.58 Million | 331.79 Million | 438.94 Million |
| Cash at end of period | 289.98 Million | 250.67 Million | 425.24 Million | 425.24 Million | 355.58 Million | 331.79 Million |
| Capital Expenditure | -450 Thousand | - | -15.01 Million | -2.51 Million | -10.37 Million | -700 Thousand |
| Effect of forex changes on cash | 12 Thousand | 25 Thousand | -26 Thousand | -27 Thousand | 45 Thousand | -51 Thousand |
| Net cash flow / Change in cash | 39.31 Million | -174.57 Million | -91.6 Million | 69.66 Million | 23.79 Million | -107.14 Million |
| Free Cash Flow | -61.07 Million | -79.69 Million | -343.22 Million | -76.92 Million | -75.17 Million | -112.58 Million |
AU
9302
AZS
PNBK
000066
RAFI